These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 26954884)
1. Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Lu L; Xia S; Ying T; Jiang S Emerg Microbes Infect; 2015 Jun; 4(6):e37. PubMed ID: 26954884 [No Abstract] [Full Text] [Related]
2. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection. Han HJ; Liu JW; Yu H; Yu XJ Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619 [TBL] [Abstract][Full Text] [Related]
3. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Yamamoto M; Matsuyama S; Li X; Takeda M; Kawaguchi Y; Inoue JI; Matsuda Z Antimicrob Agents Chemother; 2016 Nov; 60(11):6532-6539. PubMed ID: 27550352 [TBL] [Abstract][Full Text] [Related]
4. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Xia S; Liu Q; Wang Q; Sun Z; Su S; Du L; Ying T; Lu L; Jiang S Virus Res; 2014 Dec; 194():200-10. PubMed ID: 25451066 [TBL] [Abstract][Full Text] [Related]
5. MERS-CoV spike protein: a key target for antivirals. Du L; Yang Y; Zhou Y; Lu L; Li F; Jiang S Expert Opin Ther Targets; 2017 Feb; 21(2):131-143. PubMed ID: 27936982 [TBL] [Abstract][Full Text] [Related]
6. [Development of peptidic MERS-CoV entry inhibitors]. Xia S; Wang Q; Liu SW; Lu L; Jiang SB Yao Xue Xue Bao; 2015 Dec; 50(12):1513-9. PubMed ID: 27169270 [TBL] [Abstract][Full Text] [Related]
7. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Al-Tawfiq JA; Memish ZA Expert Rev Anti Infect Ther; 2017 Mar; 15(3):269-275. PubMed ID: 27937060 [TBL] [Abstract][Full Text] [Related]
8. [Small molecular agents against MERS-CoV infection]. Zeng XY; Lu L; Jiang SB; Liu SW Yao Xue Xue Bao; 2015 Dec; 50(12):1520-6. PubMed ID: 27169271 [TBL] [Abstract][Full Text] [Related]
9. Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus. Sun Y; Zhang H; Shi J; Zhang Z; Gong R Viruses; 2017 Sep; 9(9):. PubMed ID: 28906430 [TBL] [Abstract][Full Text] [Related]
10. Safe, high-throughput screening of natural compounds of MERS-CoV entry inhibitors using a pseudovirus expressing MERS-CoV spike protein. Kim JY; Kim YI; Park SJ; Kim IK; Choi YK; Kim SH Int J Antimicrob Agents; 2018 Nov; 52(5):730-732. PubMed ID: 29772395 [No Abstract] [Full Text] [Related]
11. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Corti D; Zhao J; Pedotti M; Simonelli L; Agnihothram S; Fett C; Fernandez-Rodriguez B; Foglierini M; Agatic G; Vanzetta F; Gopal R; Langrish CJ; Barrett NA; Sallusto F; Baric RS; Varani L; Zambon M; Perlman S; Lanzavecchia A Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10473-8. PubMed ID: 26216974 [TBL] [Abstract][Full Text] [Related]
12. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698 [TBL] [Abstract][Full Text] [Related]
13. Invited Editorial: MERS-CoV An Emerging Viral Zoonotic Disease: Three Years After and Counting. Memish ZA Recent Pat Antiinfect Drug Discov; 2014; 9(3):159-60. PubMed ID: 25851253 [No Abstract] [Full Text] [Related]
14. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. Rossignol JF J Infect Public Health; 2016; 9(3):227-30. PubMed ID: 27095301 [TBL] [Abstract][Full Text] [Related]
15. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing the MERS coronavirus threat. Haagmans BL; Osterhaus AD Sci Transl Med; 2014 May; 6(235):235fs19. PubMed ID: 24807556 [TBL] [Abstract][Full Text] [Related]
17. Development of Small-Molecule MERS-CoV Inhibitors. Liang R; Wang L; Zhang N; Deng X; Su M; Su Y; Hu L; He C; Ying T; Jiang S; Yu F Viruses; 2018 Dec; 10(12):. PubMed ID: 30562987 [TBL] [Abstract][Full Text] [Related]
18. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Guo X; Deng Y; Chen H; Lan J; Wang W; Zou X; Hung T; Lu Z; Tan W Immunology; 2015 Aug; 145(4):476-84. PubMed ID: 25762305 [TBL] [Abstract][Full Text] [Related]
20. A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice. Niu P; Zhao G; Deng Y; Sun S; Wang W; Zhou Y; Tan W Sci China Life Sci; 2018 Oct; 61(10):1280-1282. PubMed ID: 30091015 [No Abstract] [Full Text] [Related] [Next] [New Search]